Supreme Court Unanimously Reverses Federal Circuit in Hikma v. Amarin - ArentFox Schiff
The Supreme Court unanimously reversed the Federal Circuit in Hikma v. Amarin, ruling that a patent holder cannot use a 'skinny label' to induce infringement by generic manufacturers. This decision clarifies inducement liability for generic drug makers who carve out patented uses from their labels.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Generic/ANDA manufacturers, branded drug makers, API & contract manufacturers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately, as the ruling is effective now and may affect ongoing litigation or FDA submissions.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Supreme Court held that a generic manufacturer cannot be liable for induced infringement solely based on a 'skinny label' that carves out patented uses, unless there is evidence of active inducement. This reduces the risk of patent litigation for generics using skinny labels.
Who it affects
Generic/ANDA manufacturers, branded drug makers, API & contract manufacturers
What you must do
Review current ANDA skinny labels and ensure they do not include any language that could be construed as encouraging use for patented indications. Update labeling and promotional materials to strictly adhere to carved-out uses.
Deadline
Immediately, as the ruling is effective now and may affect ongoing litigation or FDA submissions.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)